NCT06299800 Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer
| NCT ID | NCT06299800 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Ospedaliero Universitaria Maggiore della Carita |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 779 participants |
| Start Date | 2024-02-04 |
| Primary Completion | 2025-02-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 779 participants in total. It began in 2024-02-04 with a primary completion date of 2025-02-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent research has highlighted the significant relationship between type 2 diabetes mellitus and cancer, both prevalent and impactful on global health. The intrinsic correlation arises from shared metabolic processes, particularly a systemic and chronic inflammatory state driven by factors like obesity, dyslipidemia, and hyperglycemia. This leads to the creation of a self-sustaining microenvironment known as meta-inflammation, promoting cancer development through DNA damage, oxidative stress, and the influence of hormones like leptin. The hyperglycemic environment in diabetes contributes to cancer development, supporting the Warburg effect and insulin-related mechanisms. This study aims to identify risk factors associated with diabetes that impact tumor development and progression, crucial for guiding effective preventive strategies in clinical practice. Primary objective of the study: \- identify the risk factors affecting the occurrence of cancer in the population affected by type 2 diabetes mellitus; Secondary objectives of the study: * description of the demographic, clinical and first-line therapy characteristics of patients diagnosed with type 2 diabetes mellitus; * assess risk factors for recurrence, presence of a second tumour not related to the first and the presence of both events in patients who have had a tumor within 10 years of diagnosis of diabetes; * assess the relationship between the characteristics of patients and the time to the onset of cancer.
Eligibility Criteria
Inclusion Criteria: * Legal age * Diagnosis of type 2 diabetes mellitus Exclusion Criteria: * Diagnosis of cancer before diagnosis of type 2 diabetes * Diagnosis of diabetes secondary to other diseases * Diagnosis of diabetes secondary to other drugs * Diagnosis of diabetes following surgery
Contact & Investigator
Flavia Prodam, MD PhD
PRINCIPAL INVESTIGATOR
AOU Maggiore della Carità di Novara
Frequently Asked Questions
Who can join the NCT06299800 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06299800 currently recruiting?
Yes, NCT06299800 is actively recruiting participants. Contact the research team at flavia.prodam@med.uniupo.it for enrollment information.
Where is the NCT06299800 trial being conducted?
This trial is being conducted at Novara, Italy.
Who is sponsoring the NCT06299800 clinical trial?
NCT06299800 is sponsored by Azienda Ospedaliero Universitaria Maggiore della Carita. The principal investigator is Flavia Prodam, MD PhD at AOU Maggiore della Carità di Novara. The trial plans to enroll 779 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.